Translate Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 122
- Market Cap
- -
- Website
- http://translate.bio
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
Phase 1
Withdrawn
- Conditions
- Ornithine Transcarbamylase Deficiency
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Translate Bio, Inc.
- Registration Number
- NCT03767270
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Translate Bio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03375047
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
News
No news found